Global Adult Hemoglobinopathy Testing Strategic Business Report 2023: Players Include PerkinElmer, Streck, Thermo Fisher Scientific and Trinity Biotech

Rhea-AI Summary

The global market for Adult Hemoglobinopathy Testing is projected to grow from US$368.6 Million in 2022 to US$513.7 Million by 2030, with a CAGR of 4.2%. The U.S. market alone is estimated at US$98.2 Million, while China is expected to grow at a remarkable 6.6% CAGR, reaching US$110.4 Million by 2030. Key players include Trinity Biotech, PerkinElmer, and Thermo Fisher Scientific. Notable trends impacting growth involve post-pandemic recovery and competitive dynamics across various geographic regions.

Positive

• Market size for Adult Hemoglobinopathy Testing projected to grow from US$368.6 Million in 2022 to US$513.7 Million by 2030.
• Estimated CAGR of 4.2% indicating strong growth potential.
• U.S. market estimated at US$98.2 Million, suggesting significant revenue opportunities.
• China forecasted to grow at 6.6% CAGR, indicating expanding market presence.

Negative

• None.

DUBLIN, March 21, 2023 /PRNewswire/ -- The "Adult Hemoglobinopathy Testing: Global Strategic Business Report" report has been added to  ResearchAndMarkets.com's offering.

The global market for Adult Hemoglobinopathy Testing estimated at US$368.6 Million in the year 2022, is projected to reach a revised size of US$513.7 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2022-2030.

HPLC Test, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$314.5 Million by the end of the analysis period.

Taking into account the ongoing post pandemic recovery, growth in the Mass Spectrometry segment is readjusted to a revised 4.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $98.2 Million, While China is Forecast to Grow at 6.6% CAGR

The Adult Hemoglobinopathy Testing market in the U.S. is estimated at US$98.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$110.4 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2022 to 2030.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Select Competitors (Total 44 Featured) -

• BioMedomics Inc.
• Bio-Rad Laboratories, Inc.
• Chromsystems Instruments & Chemicals GmbH
• PerkinElmer, Inc.
• Streck, Inc.
• Thermo Fisher Scientific, Inc.
• Trinity Biotech PLC

What's New for 2023?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Adult Hemoglobinopathy Testing - Global Key Competitors Percentage Market Share in 2022 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/hmb9zc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-adult-hemoglobinopathy-testing-strategic-business-report-2023-players-include-perkinelmer-streck-thermo-fisher-scientific-and-trinity-biotech-301777464.html

SOURCE Research and Markets

FAQ

What is the current market size for Adult Hemoglobinopathy Testing?

The market size for Adult Hemoglobinopathy Testing is estimated at US$368.6 Million in 2022.

What is the projected growth rate for Adult Hemoglobinopathy Testing?

The projected growth rate for Adult Hemoglobinopathy Testing is a CAGR of 4.2% from 2022 to 2030.

How is the U.S. market for Adult Hemoglobinopathy Testing expected to perform?

The U.S. market for Adult Hemoglobinopathy Testing is estimated at US$98.2 Million in 2022.

Which companies are leading the Adult Hemoglobinopathy Testing market?

Key players in the market include Trinity Biotech, PerkinElmer, and Thermo Fisher Scientific.

What factors are driving growth in the Adult Hemoglobinopathy Testing market?

Post-pandemic recovery and increasing market demand in regions like China are driving growth.